Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYGR Voyager Therapeutics

Post-Mkt 07-10 19:18:14 EDT

3.55

+0.08

+2.31%

盘后3.76

+0.21+5.92%

19:09 EDT

High3.72	Low3.50	Vol935.25K
Open3.50	D1 Closing3.47	Amplitude6.34%
Mkt Cap196.44M	Tradable Cap159.94M	Total Shares55.34M
T/O3.35M	T/O Rate2.08%	Tradable Shares45.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VYGR","market":"US","secType":"STK","nameCN":"Voyager Therapeutics","latestPrice":3.55,"timestamp":1752177600000,"preClose":3.47,"halted":0,"volume":935254,"hourTrading":{"tag":"盘后","latestPrice":3.76,"preClose":3.55,"latestTime":"19:09 EDT","volume":13883,"amount":51127.1115205,"timestamp":1752188964434},"delay":0,"floatShares":45052322,"shares":55336446,"eps":-1.460835,"marketStatus":"Post-Mkt","change":0.08,"latestTime":"07-10 19:18:14 EDT","open":3.5,"high":3.72,"low":3.5,"amount":3350044.5689242,"amplitude":0.063401,"askPrice":3.8,"askSize":31,"bidPrice":3.5,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-1.460835,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1752192000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1447218000000,"exchange":"NASDAQ","adjPreClose":3.47,"preHourTrading":{"tag":"盘前","latestPrice":3.46,"preClose":3.47,"latestTime":"09:25 EDT","volume":4632,"amount":16352.5543344,"timestamp":1752153922422},"postHourTrading":{"tag":"盘后","latestPrice":3.76,"preClose":3.55,"latestTime":"19:09 EDT","volume":13883,"amount":51127.1115205,"timestamp":1752188964434},"volumeRatio":1.644586,"impliedVol":1.0019,"impliedVolPercentile":0.48},"requestUrl":"/m/hq/s/VYGR","defaultTab":"news","newsList":[{"id":"2548196580","title":"H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2548196580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548196580?lang=en_us&edition=full_marsco","pubTime":"2025-07-01 00:15","pubTimestamp":1751300156,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report) today and set a price target of $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-voyager-therapeutics-vygr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-voyager-therapeutics-vygr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2541622005","title":"Voyager Therapeutics Inc. Concluded Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541622005","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541622005?lang=en_us&edition=full_marsco","pubTime":"2025-06-06 04:14","pubTimestamp":1749154458,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. held its annual meeting of stockholders on June 3, 2025. During the meeting, several proposals were voted on. Grace E. Colón, Ph.D., Catherine J. Mackey, Ph.D., Glenn Pierce, M.D., Ph.D., and George Scangos, Ph.D., were elected as Class I directors. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL1b8cb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2533624753","title":"U.S. RESEARCH ROUNDUP-Datadog, Masimo, Waters","url":"https://stock-news.laohu8.com/highlight/detail?id=2533624753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533624753?lang=en_us&edition=full_marsco","pubTime":"2025-05-07 15:10","pubTimestamp":1746601844,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Datadog, Masimo, WatersMay 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Datadog, Masimo and W","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL4N3RF0O2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AL","DDOG","VRNS","ZTS","LU2360107671.USD","ENR","LU1668664300.SGD","BK4528","BALL","BK4612","LU0882574055.USD","MASI","VYGR","LU1852331112.SGD","BL","KVYO","LU1861215975.USD","LU1989764664.SGD","ARMK","BK4614","LU2404859667.USD","GB00B4LPDJ14.GBP","LU0079474960.USD","BK4605","LCII","GPN","LU0390134368.USD","BK4124","WAT","BK4018","LU0205193047.USD","BK4535","EXPD","IQV","JAMF","LU1861217088.USD","XMTR","BK4573","GFS","LU1242518857.USD","IE00B3S45H60.SGD","LU1242518931.SGD","LU0240878834.USD","LU0642271901.SGD","LU0158827948.USD","DOCN","LU2211814178.USD"],"gpt_icon":1},{"id":"2533966778","title":"Voyager Therapeutics Q1 EPS $(0.53) Misses $(0.46) Estimate, Sales $6.47M Miss $13.56M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533966778","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533966778?lang=en_us&edition=full_marsco","pubTime":"2025-05-07 04:42","pubTimestamp":1746564120,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.46) by 15.22 percent. This is a 165 percent decrease over losses of $(0.20) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45237219/voyager-therapeutics-q1-eps-0-53-misses-0-46-estimate-sales-6-47m-miss-13-56m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2533662928","title":"Voyager Therapeutics Inc:  Ended Q1 With Cash Position of $295 Mln Which We Expect to Provide Runway Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2533662928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533662928?lang=en_us&edition=full_marsco","pubTime":"2025-05-07 04:01","pubTimestamp":1746561661,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nPLX78D2A4:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2531341260","title":"Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531341260","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531341260?lang=en_us&edition=full_marsco","pubTime":"2025-04-29 04:30","pubTimestamp":1745872200,"startTime":"0","endTime":"0","summary":"- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg -. - Featured data also include anti-amyloid gene therapy for Alzheimer’s disease, as well as multiple presentations on Voyager’s continued enhancements to its highly BBB penetrant novel capsids -. LEXINGTON, Mass., April 28, 2025  -- Voyager Therapeutics, Inc. , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced eight oral and poster presentations at the upcoming American Society of Gene & Cell Therapy’s  28th annual meeting taking place in New Orleans, May 13-17, 2025.Cross-species BBB-penetrant IV-delivered AAV gene therapy provides broad and robust CNS tau lowering in tauopathy mouse models and non-human primate . Hechen Bao, Ph.D., Scientist II, Neuroscience. Tuesday, May 13, 2025, 6:00 p.m. – 7:30 p.m. CT. Oral Presentation: Discovery of AAV9-derived ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voyager-next-generation-cns-capsids-203000971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","BK4135","VYGR","BK4139"],"gpt_icon":0},{"id":"2529353365","title":"Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2529353365","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529353365?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 04:33","pubTimestamp":1745267614,"startTime":"0","endTime":"0","summary":"Cash: $332 million as of the end of 2024.Potential Future Milestone Payments: $8.2 billion from partnerships.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Voyager Therapeutics Inc  has a robust pipeline with 4 wholly owned and 13 partnered programs, providing multiple opportunities for clinical data generation.The company reported $332 million in cash at the end of 2024, with potential future milestone payments totaling $8.2 billion, indicating strong financial health.Voyager's partnerships have been a significant source of non-diluted revenue, contributing to its financial stability.A: Alfred Sandrock, CEO, mentioned that they expect to see data from bepranemab, focusing on exposure PD relationships and the decrease in tau spreading necessary for a clinically relevant effect. They are also interested in subgroup efficacy, such as the impact of ApoE e4 carrier status and initial tau burden. Other companies, like ASI, are sharing dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voyager-therapeutics-inc-vygr-q4-203334528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYGR"],"gpt_icon":0},{"id":"2526397528","title":"Promising Developments in Alzheimer’s Treatments Support Buy Rating for Voyager Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2526397528","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526397528?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 00:35","pubTimestamp":1744216519,"startTime":"0","endTime":"0","summary":"Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Voyager Therapeutics (VYGR – Research Report). The associated price target is ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-alzheimers-treatments-support-buy-rating-for-voyager-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-alzheimers-treatments-support-buy-rating-for-voyager-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2526907849","title":"Voyager Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2526907849","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526907849?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 01:46","pubTimestamp":1744134360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 13:46 ET (17:46 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2526784844","title":"Promising Developments in Voyager Therapeutics’ Alzheimer’s Programs Highlight Potential of Dual Tau-Targeted Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2526784844","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526784844?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 00:15","pubTimestamp":1744128922,"startTime":"0","endTime":"0","summary":"Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics (VYGR – Research Report), retaining the price target of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-voyager-therapeutics-alzheimers-programs-highlight-potential-of-dual-tau-targeted-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-voyager-therapeutics-alzheimers-programs-highlight-potential-of-dual-tau-targeted-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2525895114","title":"TD Cowen Keeps Their Buy Rating on Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525895114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525895114?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 19:36","pubTimestamp":1744112219,"startTime":"0","endTime":"0","summary":"In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report). The company’s share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-voyager-therapeutics-vygr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-voyager-therapeutics-vygr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","VYGR","COWN"],"gpt_icon":0},{"id":"2525765387","title":"Top Executives Unload Thousands of Voyager Therapeutics Shares!","url":"https://stock-news.laohu8.com/highlight/detail?id=2525765387","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525765387?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 10:01","pubTimestamp":1743818471,"startTime":"0","endTime":"0","summary":"New insider activity at Voyager Therapeutics ( ($VYGR) ) has taken place on April 5, 2025. In recent transactions involving Voyager Therapeutics st...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-unload-thousands-of-voyager-therapeutics-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-unload-thousands-of-voyager-therapeutics-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2523910763","title":"Voyager Therapeutics announces new data from two preclinical programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2523910763","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523910763?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:20","pubTimestamp":1743420050,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on tau...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-announces-new-data-from-two-preclinical-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-announces-new-data-from-two-preclinical-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2520564793","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Teleflex (TFX) and Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520564793","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520564793?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 14:30","pubTimestamp":1742193028,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX – Research Report) and Voyager Therapeutics (VYGR –...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-teleflex-tfx-and-voyager-therapeutics-vygr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-teleflex-tfx-and-voyager-therapeutics-vygr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4585","BK4588","TFX","BK4504","BK4139","VYGR","BK4082","HCSG"],"gpt_icon":0},{"id":"2520556199","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520556199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520556199?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 14:21","pubTimestamp":1742192460,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report), Labco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-labcorp-holdings-lh-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-labcorp-holdings-lh-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0006061336.USD","BK4139","BK4550","BK4137","LU1059921491.USD","LH","VYGR","BK4196","HCSG","ARQT","BK4585","BK4588"],"gpt_icon":0},{"id":"2519548538","title":"Voyager Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2519548538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519548538?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 00:26","pubTimestamp":1741883160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 12:26 ET (16:26 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2519884939","title":"Voyager Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2519884939","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519884939?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:28","pubTimestamp":1741861680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 06:28 ET (10:28 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2519881024","title":"Voyager Therapeutics: Strong Buy Rating Backed by Strategic Partnerships and Promising Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2519881024","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519881024?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:17","pubTimestamp":1741861039,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strong-buy-rating-backed-by-strategic-partnerships-and-promising-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strong-buy-rating-backed-by-strategic-partnerships-and-promising-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2518108072","title":"Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2518108072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518108072?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 11:35","pubTimestamp":1741750516,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating on March 3. Phil Nadeau has given his Buy ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strong-financials-and-promising-pipeline-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strong-financials-and-promising-pipeline-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2518196705","title":"Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2518196705","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518196705?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 05:10","pubTimestamp":1741727404,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics  came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -68.57%. A quarter ago, it was expected that this gene therapy company would post a loss of $0.45 per share when it actually produced a loss of $0.16, delivering a surprise of 64.44%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Voyager Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.28 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 68.81%. This compares to year-ago revenues of $90.06 million. The company has topped consensus revenue estimates three times over the last four quarters.Voyager Therapeutics shares have lost about 26.5% since the beginning of the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voyager-therapeutics-vygr-reports-q4-211004646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYGR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.voyagertherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0844},{"period":"1month","weight":0.0358},{"period":"3month","weight":0.1605},{"period":"6month","weight":-0.3633},{"period":"1year","weight":-0.5652},{"period":"ytd","weight":-0.388}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1896},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.0648}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.005473},{"month":2,"riseRate":0.5,"avgChangeRate":0.058533},{"month":3,"riseRate":0.5,"avgChangeRate":0.047541},{"month":4,"riseRate":0.5,"avgChangeRate":0.019214},{"month":5,"riseRate":0.6,"avgChangeRate":0.041264},{"month":6,"riseRate":0.5,"avgChangeRate":0.010419},{"month":7,"riseRate":0.4,"avgChangeRate":-0.010023},{"month":8,"riseRate":0.555556,"avgChangeRate":-0.028879},{"month":9,"riseRate":0.111111,"avgChangeRate":0.036077},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.01151},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.073556},{"month":12,"riseRate":0.5,"avgChangeRate":-0.035937}],"exchange":"NASDAQ","name":"Voyager Therapeutics","nameEN":"Voyager Therapeutics"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Voyager Therapeutics,VYGR,Voyager Therapeutics股票,Voyager Therapeutics股票老虎,Voyager Therapeutics股票老虎国际,Voyager Therapeutics行情,Voyager Therapeutics股票行情,Voyager Therapeutics股价,Voyager Therapeutics股市,Voyager Therapeutics股票价格,Voyager Therapeutics股票交易,Voyager Therapeutics股票购买,Voyager Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}